脓毒症危重成人的液体治疗:综述
该综述指出ICU约20%至30%的患者有脓毒症,液体治疗从急诊开始并贯穿ICU。液体治疗可分为复苏、优化、稳定和清除四个重叠阶段。3项RCT(3723例)显示目标导向治疗未降低死亡率(24.9% vs 25.4%,P=.68);另两项RCT分别显示优先升压药(14.0% vs 14.9%,P=.61)和限制液体(42.3% vs 42.1%,P=.96)未改善死亡率。清除期限制液体并使用利尿剂可增加无机械通气天数(14.6 vs 12.1天,P<.001),羟乙基淀粉增加肾替代治疗发生率(7.0% vs 5.8%,P=.04)。作者认为应分阶段权衡液体利弊、避免羟乙基淀粉、促进ARDS恢复期液体清除。
要点
- 脓毒症液体治疗分四阶段:复苏、优化、稳定、清除,各阶段需权衡利弊。
- 3项RCT(3723例)显示目标导向治疗(CVP 8-12 mm Hg、MAP 65-90 mm Hg、ScvO2≥70%)未降低死亡率(24.9% vs 25.4%,P=.68)。
- 脓毒症低血压患者(1563例)优先升压药未改善死亡率(14.0% vs 14.9%,P=.61)。
- 脓毒症休克患者(1554例)限制液体未降低死亡率(42.3% vs 42.1%,P=.96)。
- ARDS清除期限制液体并用利尿剂增加无机械通气天数(14.6 vs 12.1天,P<.001);羟乙基淀粉增加肾替代治疗(7.0% vs 5.8%,P=.04)。
适用人群与场景
- ICU脓毒症成人患者,液体治疗通常始于急诊科,ICU静脉液体是脓毒症治疗的重要组成部分。
处置流程与药物剂量
- 液体治疗分为4个重叠阶段:复苏期快速补液恢复灌注;优化期评估额外液体的风险与获益以治疗休克并确保器官灌注;稳定期仅在存在液体反应性信号时使用液体治疗;清除期清除危重病治疗期间积累的过多液体。
- 避免使用羟乙基淀粉。
- 对于从急性呼吸窘迫综合征恢复的患者,促进液体清除。
研究设计与关键结果
- 综述纳入多项RCT:3723例脓毒症患者接受1至2 L液体后,3项RCT报告目标导向治疗(液体团注达CVP 8-12 mm Hg、升压药达MAP 65-90 mm Hg、红细胞输注或正性肌力药达ScvO2至少70%)与无结构化临床 care 相比未降低死亡率(24.9% vs 25.4%;P=.68)。
- 1563例脓毒症低血压患者接受1 L液体后,一项RCT报告优先升压药治疗与进一步液体治疗相比未改善死亡率(14.0% vs 14.9%;P=.61)。
- 另一项RCT报告1554例ICU脓毒症休克患者接受至少1 L液体后,与更宽松液体管理相比,在无严重低灌注时限制液体未降低死亡率(42.3% vs 42.1%;P=.96)。
- 一项1000例急性呼吸窘迫患者的RCT报告,在清除期限制液体并使用利尿剂与达到更高心内压的液体治疗相比,改善无机械通气天数(14.6 vs 12.1天;P<.001),并报告羟乙基淀粉与生理盐水相比显著增加肾替代治疗发生率(7.0% vs 5.8%;P=.04),与乳酸林格液或醋酸林格液相比亦然。
证据类型、等级与局限
- 综述,汇总多项随机临床试验证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症最佳液体管理仍不确定,临床医生应在危重病的每个阶段考虑液体治疗的风险与获益。
- 作者认为,应避免使用羟乙基淀粉。
- 作者认为,对于从急性呼吸窘迫综合征恢复的患者,应促进液体清除。
指南或共识出处
- JAMA综述:脓毒症危重成人的液体治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Approximately 20% to 30% of patients admitted to an intensive care unit have sepsis. While fluid therapy typically begins in the emergency department, intravenous fluids in the intensive care unit are an essential component of therapy for sepsis.
OBSERVATIONS: For patients with sepsis, intravenous fluid can increase cardiac output and blood pressure, maintain or increase intravascular fluid volume, and deliver medications. Fluid therapy can be conceptualized as 4 overlapping phases from early illness through resolution of sepsis: resuscitation (rapid fluid administered to restore perfusion); optimization (the risks and benefits of additional fluids to treat shock and ensure organ perfusion are evaluated); stabilization (fluid therapy is used only when there is a signal of fluid responsiveness); and evacuation (excess fluid accumulated during treatment of critical illness is eliminated). Among 3723 patients with sepsis who received 1 to 2 L of fluid, 3 randomized clinical trials (RCTs) reported that goal-directed therapy administering fluid boluses to attain a central venous pressure of 8 to 12 mm Hg, vasopressors to attain a mean arterial blood pressure of 65 to 90 mm Hg, and red blood cell transfusions or inotropes to attain a central venous oxygen saturation of at least 70% did not decrease mortality compared with unstructured clinical care (24.9% vs 25.4%; P = .68). Among 1563 patients with sepsis and hypotension who received 1 L of fluid, an RCT reported that favoring vasopressor treatment did not improve mortality compared with further fluid administration (14.0% vs 14.9%; P = .61). Another RCT reported that among 1554 patients in the intensive care unit with septic shock treated with at least 1 L of fluid compared with more liberal fluid administration, restricting fluid administration in the absence of severe hypoperfusion did not reduce mortality (42.3% vs 42.1%; P = .96). An RCT of 1000 patients with acute respiratory distress during the evacuation phase reported that limiting fluid administration and administering diuretics improved the number of days alive without mechanical ventilation compared with fluid treatment to attain higher intracardiac pressure (14.6 vs 12.1 days; P < .001), and it reported that hydroxyethyl starch significantly increased the incidence of kidney replacement therapy compared with saline (7.0% vs 5.8%; P = .04), Ringer lactate, or Ringer acetate.
CONCLUSIONS AND RELEVANCE: Fluids are an important component of treating patients who are critically ill with sepsis. Although optimal fluid management in patients with sepsis remains uncertain, clinicians should consider the risks and benefits of fluid administration in each phase of critical illness, avoid use of hydroxyethyl starch, and facilitate fluid removal for patients recovering from acute respiratory distress syndrome.
参考来源
- Zampieri FG, Bagshaw SM, Semler MW, et al. Fluid Therapy for Critically Ill Adults With Sepsis: A Review. JAMA. 2023. PMID: 37314271. doi:10.1001/jama.2023.7560
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。